Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer

Summary

The goal of this clinical trial is to establish the fraction of patients that achieve a major pathological response (MPR) after 9 cycles of pembrolizumab, with the ultimate aim of informing a follow-up randomized trial. Participants will receive 9 cycles of pembrolizumab before their standard of care hysterectomy.

Timeline

Start

2023-12-01

Primary completion

2027-12-30

Completion

2028-01

Drugs

Indications